Human Genome Epidemiology Literature Finder
Records 1 - 9 (of 9 Records) |
Query Trace: Breast Neoplasms and EPHA5[original query] |
---|
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Jul . Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson E, Witte JS, Shulman L, Nakamura Y, Ratain MJ, Kroetz D |
Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. British journal of cancer 2016 Oct . Lam Siu W, Frederiks Charlotte N, van der Straaten Tahar, Honkoop Aafke H, Guchelaar Henk-Jan, Boven Ep |
Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients. Oncotarget 2017 Sep 8 (37): 61538-61550. Jeong Hae Min, Kim Ryong Nam, Kwon Mi Jeong, Oh Ensel, Han Jinil, Lee Se Kyung, Choi Jong-Sun, Park Sara, Nam Seok Jin, Gong Gyung Yup, Nam Jin Wu, Choi Doo Ho, Lee Hannah, Nam Byung-Ho, Choi Yoon-La, Shin Young K |
Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer. Clinical Medicine Insights. Oncology 2019 13 1179554919868482. Saravia César H, Flores Claudio, Schwarz Luis J, Bravo Leny, Zavaleta Jenny, Araujo Jhajaira, Neciosup Silvia, Pinto Joseph |
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. The oncologist 2019 4 24 (11): e1024-e1033. Ciruelos Eva, Apellániz-Ruiz María, Cantos Blanca, Martinez-Jáñez Noelia, Bueno-Muiño Coralia, Echarri Maria-Jose, Enrech Santos, Guerra Juan-Antonio, Manso Luis, Pascual Tomas, Dominguez Cristina, Gonzalo Juan-Francisco, Sanz Juan-Luis, Rodriguez-Antona Cristina, Sepúlveda Juan-Manu |
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy. British journal of clinical pharmacology 2019 12 86 (5): 880-890. Marcath Lauren A, Kidwell Kelley M, Vangipuram Kiran, Gersch Christina L, Rae James M, Burness Monika L, Griggs Jennifer J, Van Poznak Catherine, Hayes Daniel F, Smith Ellen M Lavoie, Henry N Lynn, Beutler Andreas S, Hertz Daniel |
EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma. Cancer gene therapy 2020 8 28 (7-8): 864-874. Huang Weimei, Lin Anqi, Luo Peng, Liu Yuchen, Xu Wentao, Zhu Weiliang, Wei Ting, Lyu Qingwen, Guo Linlang, Zhang Ji |
Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis. Clinical and translational science 2022 Jul . Guijosa Alberto, Freyria Ana, Espinosa-Fernandez Jose Rodrigo, Estrada-Mena Francisco J, Armenta-Quiroga Ana Sofía, Ortega-Treviño Maria Fernanda, Catalán Rodrigo, Antonio-Aguirre Bani, Villarreal-Garza Cynthia, Perez-Ortiz Andric |
Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients. Acta medica Okayama 2022 12 76 (6): 661-671. Abe Yuko, Taira Naruto, Kashiwabara Kosuke, Tsurutani Junji, Kitada Masahiro, Takahashi Masato, Kato Hiroaki, Kikawa Yuichiro, Sakata Eiko, Naito Yoichi, Hasegawa Yoshie, Saito Tsuyoshi, Iwasa Tsutomu, Takashima Tsutomu, Aihara Tomohiko, Mukai Hirofumi, Hara Fumikata, Shien Tadahiko, Doihara Hiroyoshi, Toyooka Shinic |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source: